Table 2b.
General primary outcomes from clinical trials
| Primary outcomes | Heparin | Rivaroxaban | Apixaban | Edoxaban | Dabigatran | Warfarin |
|---|---|---|---|---|---|---|
| Thrombotic events | 6 | 1 | 0 | 0 | 0 | 0 |
| Mortality | 38 | 7 | 2 | 3 | 1 | 1 |
| ICU admission | 11 | 0 | 0 | 0 | 0 | 0 |
| Hospitalization | 9 | 7 | 1 | 0 | 0 | 0 |
| Ventilation | 47 | 7 | 2 | 0 | 0 | 0 |
| PaO2/FiO2 ratio | 6 | 0 | 0 | 0 | 0 | 0 |